There’s a lot to be optimistic about in the Services sector as 3 analysts just weighed in on Trip.com Group Ltd. Sponsored ADR (TCOM – Research Report), UniFirst (UNF – Research Report) and Cintas (CTAS – Research Report) with bullish sentiments.
Trip.com Group Ltd. Sponsored ADR (TCOM)
Deutsche Bank analyst Leo Chiang maintained a Buy rating on Trip.com Group Ltd. Sponsored ADR on June 30 and set a price target of $35.00. The company’s shares closed last Friday at $27.79.
According to TipRanks.com, Chiang is a 1-star analyst with an average return of
Trip.com Group Ltd. Sponsored ADR has an analyst consensus of Strong Buy, with a price target consensus of $31.70, a 17.1% upside from current levels. In a report issued on June 28, Mizuho Securities also maintained a Buy rating on the stock with a $30.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
UniFirst (UNF)
In a report issued on June 29, Andrew Wittmann from Robert W. Baird maintained a Buy rating on UniFirst, with a price target of $195.00. The company’s shares closed last Friday at $172.50.
According to TipRanks.com, Wittmann is a 5-star analyst with an average return of
Currently, the analyst consensus on UniFirst is a Moderate Buy with an average price target of $195.00.
Cintas (CTAS)
Deutsche Bank analyst Faiza Alwy maintained a Buy rating on Cintas yesterday and set a price target of $465.00. The company’s shares closed last Friday at $376.71.
According to TipRanks.com, Alwy is ranked #4885 out of 7906 analysts.
Currently, the analyst consensus on Cintas is a Moderate Buy with an average price target of $432.33.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on TCOM:
- Blueprint Medicines (BPMC) Gets a Buy Rating from Robert W. Baird
- SVB Securities Believes Eli Lilly & Co (LLY) Won’t Stop Here
- SVB Securities Thinks Avadel Pharmaceuticals’ Stock is Going to Recover
- Vertex Pharmaceuticals (VRTX) Receives a Hold from SVB Securities
- Sanofi (SNYNF) Gets a Buy Rating from SVB Securities